Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, UnitedHealth Group and AbbVie. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$794.67 -104.28 (-11.60%)
Closing price 03:59 PM Eastern
Extended Trading
$798.54 +3.87 (+0.49%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $828, reflecting strong market interest and potential for growth.
  • Eli Lilly and Co has a high return on equity, indicating effective management and profitability, which can lead to higher shareholder returns.
  • The company has a robust net margin, suggesting efficient operations and the ability to convert revenue into profit.

Cons of Eli Lilly and Company

  • The company recently missed earnings expectations, which could raise concerns about its short-term performance and market competitiveness.
  • High valuation metrics, such as a PE ratio above 70, may suggest that the stock is overvalued compared to its earnings, posing a risk for investors.
  • Insider ownership is relatively low, which might indicate a lack of confidence from company executives in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$852.36 billion
P/E Ratio
67.86
Consensus Rating
Moderate Buy
Consensus Price Target
$1,000.32 (+25.9% Upside)
Volume
12.58 million shares
Average Volume
3.47 million shares
Today's Range
$792.07
$850.93
50-Day Range
$719.85
$930.22
52-Week Range
$677.09
$972.53
Dividend Yield
0.68%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$154.42 -1.89 (-1.21%)
Closing price 03:59 PM Eastern
Extended Trading
$154.50 +0.08 (+0.05%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $157.68, which may present a buying opportunity for investors looking for value in a well-established company.
  • Johnson & Johnson has a strong market capitalization of approximately $380 billion, indicating its stability and ability to weather economic fluctuations.
  • Recent analyst ratings show a consensus of "Moderate Buy," with several analysts issuing buy ratings, suggesting positive sentiment about the company's future performance.

Cons of Johnson & Johnson

  • Recent insider trading activity shows a decrease in ownership by corporate insiders, which may raise concerns about their confidence in the company's future.
  • Some analysts have lowered their price targets for the stock, indicating potential challenges ahead that could affect its performance.
  • The company has a relatively high price-to-earnings-growth ratio of 2.56, which may suggest that the stock is overvalued compared to its growth rate.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$376.09 billion
P/E Ratio
23.22
Consensus Rating
Moderate Buy
Consensus Price Target
$171.82 (+11.3% Upside)
Volume
7.32 million shares
Average Volume
7.89 million shares
Today's Range
$153.36
$155.09
50-Day Range
$148.62
$167.57
52-Week Range
$140.68
$169.99
Dividend Yield
3.18%
UnitedHealth Group stock logo

3. UnitedHealth Group NYSE:UNH

$400.07 -11.37 (-2.76%)
Closing price 03:59 PM Eastern
Extended Trading
$400.15 +0.08 (+0.02%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $433, which reflects a potential upside based on recent analyst price targets.
  • UnitedHealth Group has received multiple "outperform" ratings from analysts, indicating strong confidence in its future performance.
  • The company reported a robust revenue of over $109 billion in its latest earnings, showcasing its strong market position and operational efficiency.

Cons of UnitedHealth Group

  • The stock has experienced a decline from its 52-week high of around $630, which may indicate volatility and potential risks in the market.
  • Recent earnings results showed a slight miss on EPS estimates, which could raise concerns about the company's short-term performance.
  • Analysts have recently lowered price targets, suggesting a more cautious outlook on the stock's future growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$374.50 billion
P/E Ratio
25.81
Consensus Rating
Buy
Consensus Price Target
$596.86 (+49.2% Upside)
Volume
9.29 million shares
Average Volume
4.57 million shares
Today's Range
$399.86
$411.99
50-Day Range
$400.07
$599.10
52-Week Range
$399.86
$630.73
Dividend Yield
2.05%
AbbVie stock logo

4. AbbVie NYSE:ABBV

$193.40 -1.71 (-0.87%)
Closing price 03:59 PM Eastern
Extended Trading
$192.88 -0.52 (-0.27%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $197, which is near its 1-year high of $218.66, indicating strong market performance.
  • AbbVie has a robust return on equity of over 296%, showcasing its efficiency in generating profits from shareholders' equity.
  • The company recently announced a quarterly dividend of $1.64 per share, translating to an annualized dividend yield of 3.70%, which can provide a steady income stream for investors.

Cons of AbbVie

  • The company reported earnings per share of $2.16, missing analysts' expectations by $0.82, which may raise concerns about its short-term financial performance.
  • AbbVie has a high dividend payout ratio of 273.33%, indicating that it is returning a significant portion of its earnings to shareholders, which could limit funds available for reinvestment in growth.
  • With a net margin of only 7.59%, there may be concerns about the company's profitability compared to its peers in the pharmaceutical industry.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$342.11 billion
P/E Ratio
80.58
Consensus Rating
Moderate Buy
Consensus Price Target
$211.41 (+9.3% Upside)
Volume
5.82 million shares
Average Volume
6.08 million shares
Today's Range
$189.80
$195.82
50-Day Range
$170.01
$216.62
52-Week Range
$153.58
$218.66
Dividend Yield
3.64%
Novo Nordisk A/S stock logo

5. Novo Nordisk A/S NYSE:NVO

$65.67 -0.78 (-1.17%)
Closing price 03:59 PM Eastern
Extended Trading
$65.67 +0.00 (+0.00%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $61, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Recent earnings reports show that Novo Nordisk has consistently exceeded earnings expectations, with a reported EPS of $0.91, surpassing the consensus estimate.
  • The company has a strong return on equity of 84.68%, suggesting effective management and profitability, which can be attractive to investors looking for solid financial performance.

Cons of Novo Nordisk A/S

  • The stock has experienced significant volatility, with a 52-week high of $148.15 and a low of $57.00, which may concern risk-averse investors.
  • Despite recent gains, the stock's price-to-earnings (P/E) ratio of around 18.63 may suggest that it is overvalued compared to industry peers, potentially limiting future upside.
  • There is a high level of competition in the pharmaceutical sector, which could impact Novo Nordisk's market share and profitability in the long term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$294.70 billion
P/E Ratio
19.96
Consensus Rating
Hold
Consensus Price Target
$135.00 (+105.6% Upside)
Volume
16.43 million shares
Average Volume
6.20 million shares
Today's Range
$64.18
$68.83
50-Day Range
$57.99
$90.94
52-Week Range
$57.00
$148.15
Dividend Yield
2.64%
Novartis stock logo

6. Novartis NYSE:NVS

$111.23 -2.26 (-1.99%)
Closing price 03:59 PM Eastern
Extended Trading
$111.28 +0.05 (+0.05%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The current stock price is around $111.52, reflecting a stable performance in the market.
  • Recent upgrades from multiple analysts, including a "strong-buy" rating from BNP Paribas, indicate positive sentiment and potential for growth.
  • Institutional investors own approximately 13.12% of the company's stock, suggesting confidence from large financial entities.

Cons of Novartis

  • Despite recent upgrades, there are still three analysts who have rated the stock with a sell rating, indicating some skepticism about its future performance.
  • The stock has a price-to-earnings ratio of 18.83, which may be considered high compared to industry averages, potentially limiting upside for new investors.
  • Recent trading volumes have shown fluctuations, with volumes sometimes falling below average, which could indicate reduced investor interest.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$234.96 billion
P/E Ratio
18.92
Consensus Rating
Hold
Consensus Price Target
$123.38 (+10.9% Upside)
Volume
2.09 million shares
Average Volume
1.56 million shares
Today's Range
$110.43
$112.65
50-Day Range
$101.80
$115.60
52-Week Range
$96.06
$120.92
Dividend Yield
2.32%
Abbott Laboratories stock logo

7. Abbott Laboratories NYSE:ABT

$130.96 +0.21 (+0.16%)
Closing price 03:59 PM Eastern
Extended Trading
$131.77 +0.81 (+0.62%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance.
  • The current stock price is around $131.81, which is near its 1-year high of $141.23, suggesting potential for further growth.
  • Recent upgrades in price targets by major firms, such as Goldman Sachs raising it to $154.00, reflect positive market sentiment and expectations for the company's performance.

Cons of Abbott Laboratories

  • Insider selling has been observed, with significant shares sold recently, which may raise concerns about the executives' confidence in the company's future.
  • Despite positive ratings, there are still four analysts who have rated the stock as a hold, suggesting some uncertainty about its short-term performance.
  • The stock has experienced fluctuations, with a 1-year low of $99.71, indicating potential volatility that could affect investor returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$227.12 billion
P/E Ratio
17.12
Consensus Rating
Moderate Buy
Consensus Price Target
$142.59 (+8.9% Upside)
Volume
6.76 million shares
Average Volume
6.09 million shares
Today's Range
$128.00
$131.63
50-Day Range
$123.63
$140.13
52-Week Range
$99.71
$141.23
Dividend Yield
1.82%
AstraZeneca stock logo

8. AstraZeneca NASDAQ:AZN

$70.51 -1.28 (-1.78%)
Closing price 04:00 PM Eastern
Extended Trading
$70.68 +0.17 (+0.25%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $72, which reflects a stable position in the market.
  • AstraZeneca has recently increased its semi-annual dividend to $1.03 per share, up from $0.49, indicating strong financial health and a commitment to returning value to shareholders.
  • The company has a robust return on equity of over 32%, suggesting effective management and profitability relative to shareholder equity.

Cons of AstraZeneca

  • The company reported earnings per share of $1.05, which was below the consensus estimate of $1.10, raising concerns about its short-term profitability.
  • AstraZeneca's quick ratio of 0.74 and current ratio of 0.93 suggest potential liquidity issues, as these ratios indicate that the company may struggle to cover its short-term liabilities.
  • Despite a solid market position, the stock has shown volatility, with a beta of 0.49, which may deter investors looking for stable returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$218.67 billion
P/E Ratio
31.20
Consensus Rating
Buy
Consensus Price Target
$88.00 (+24.8% Upside)
Volume
5.82 million shares
Average Volume
5.17 million shares
Today's Range
$69.70
$70.70
50-Day Range
$64.87
$77.96
52-Week Range
$61.24
$87.68
Dividend Yield
2.96%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$83.30 -1.90 (-2.23%)
Closing price 03:59 PM Eastern
Extended Trading
$83.40 +0.10 (+0.12%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $79, showing a recent increase of 0.4%, which may indicate positive market sentiment.
  • Merck has a strong net margin of approximately 26.67%, suggesting efficient management and profitability, which can lead to higher returns for investors.
  • The company has announced a significant share buyback program worth $10 billion, indicating that the board believes the stock is undervalued and is committed to returning value to shareholders.

Cons of Merck & Co., Inc.

  • The company reported earnings per share (EPS) of $1.72 for the latest quarter, missing the consensus estimate of $1.85, which may raise concerns about its short-term performance.
  • Several brokerages have downgraded their ratings on Merck, with price targets being reduced, indicating a cautious outlook from analysts.
  • Insider selling activity has been noted, with one insider selling a significant number of shares, which could be interpreted as a lack of confidence in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$210.06 billion
P/E Ratio
12.38
Consensus Rating
Moderate Buy
Consensus Price Target
$111.13 (+33.4% Upside)
Volume
10.03 million shares
Average Volume
12.01 million shares
Today's Range
$83.17
$84.58
50-Day Range
$76.42
$95.13
52-Week Range
$75.93
$134.63
Dividend Yield
3.92%
Intuitive Surgical stock logo

10. Intuitive Surgical NASDAQ:ISRG

$517.18 +1.38 (+0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$516.39 -0.79 (-0.15%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $487, which reflects a strong market interest in the company's innovative surgical technologies.
  • Intuitive Surgical, Inc. has consistently reported strong earnings, with recent quarterly results showing earnings per share exceeding analysts' expectations, indicating robust financial health.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, with a significant number of buy ratings suggesting positive future performance.

Cons of Intuitive Surgical

  • The stock has a high P/E ratio, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been significant, with executives selling over 33,000 shares recently, which could signal a lack of confidence in the company's short-term prospects.
  • Market volatility, as indicated by a beta of 1.55, suggests that the stock may experience larger price swings, which could be risky for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$185.37 billion
P/E Ratio
80.68
Consensus Rating
Moderate Buy
Consensus Price Target
$598.95 (+15.8% Upside)
Volume
1.67 million shares
Average Volume
1.62 million shares
Today's Range
$512.67
$524.44
50-Day Range
$451.58
$580.93
52-Week Range
$367.39
$616.00
Dividend Yield
N/A
Thermo Fisher Scientific stock logo

11. Thermo Fisher Scientific NYSE:TMO

$419.88 -9.12 (-2.13%)
Closing price 03:59 PM Eastern
Extended Trading
$419.66 -0.22 (-0.05%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $432, which reflects a significant market capitalization of approximately $163.19 billion, indicating strong investor confidence in the company's future prospects.
  • Thermo Fisher Scientific Inc. has a low payout ratio of 10.41%, suggesting that the company retains a large portion of its earnings for reinvestment, which could lead to future growth and increased shareholder value.
  • Recent analyst ratings show a consensus of "Moderate Buy," with multiple firms setting target prices above the current stock price, indicating potential for price appreciation.

Cons of Thermo Fisher Scientific

  • Insider selling has been observed, with significant shares sold recently by executives, which may raise concerns about their confidence in the company's future performance.
  • Despite a strong market position, the stock has experienced fluctuations, with a recent decline of about 0.6%, indicating potential volatility that could affect short-term investors.
  • Some analysts have set target prices below the current stock price, suggesting that there may be a lack of consensus on the stock's near-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$158.50 billion
P/E Ratio
25.40
Consensus Rating
Moderate Buy
Consensus Price Target
$607.43 (+44.7% Upside)
Volume
2.77 million shares
Average Volume
1.76 million shares
Today's Range
$415.38
$428.87
50-Day Range
$417.57
$539.86
52-Week Range
$409.85
$627.88
Dividend Yield
0.41%
Boston Scientific stock logo

12. Boston Scientific NYSE:BSX

$103.16 +0.29 (+0.28%)
Closing price 03:59 PM Eastern
Extended Trading
$103.30 +0.14 (+0.13%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $99, reflecting a recent increase of 4.2%, indicating positive market sentiment and potential for further growth.
  • Boston Scientific Co. reported earnings per share of $0.70, surpassing analysts' expectations, which suggests strong financial performance and effective management.
  • Analysts have a consensus rating of "Buy" for Boston Scientific Co., with a price target averaging around $110.22, indicating confidence in the company's future growth potential.

Cons of Boston Scientific

  • The price-to-earnings ratio is relatively high at 79.21, which may suggest that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite strong earnings, the company has a net margin of 11.07%, which may indicate challenges in maintaining profitability in a competitive market.
  • Insider sales have occurred recently, with significant shares sold, which could raise concerns about the executives' confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$152.59 billion
P/E Ratio
82.53
Consensus Rating
Buy
Consensus Price Target
$114.52 (+11.0% Upside)
Volume
8.21 million shares
Average Volume
6.35 million shares
Today's Range
$101.51
$103.83
50-Day Range
$89.78
$104.82
52-Week Range
$70.97
$107.17
Dividend Yield
N/A
Amgen stock logo

13. Amgen NASDAQ:AMGN

$283.78 -7.14 (-2.45%)
Closing price 04:00 PM Eastern
Extended Trading
$286.01 +2.23 (+0.79%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $280.84, which may present a buying opportunity for investors looking for value in the biotech sector.
  • Amgen Inc. has a strong market capitalization of approximately $150.99 billion, indicating a solid financial foundation and stability in the market.
  • Recent analyst ratings show a consensus rating of "Hold" with a target price of $310.57, suggesting potential upside for investors.

Cons of Amgen

  • Insiders have sold a total of 69,341 shares valued at over $20 million in the last ninety days, which may raise concerns about the company's short-term outlook.
  • The company has a high debt-to-equity ratio of 9.62, indicating that it relies heavily on debt financing, which can be risky if market conditions change.
  • Recent reports have shown mixed reactions to Amgen's product data, which could impact investor confidence and stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$152.57 billion
P/E Ratio
37.59
Consensus Rating
Hold
Consensus Price Target
$310.57 (+9.4% Upside)
Volume
2.94 million shares
Average Volume
2.79 million shares
Today's Range
$282.07
$287.88
50-Day Range
$273.68
$327.36
52-Week Range
$253.30
$346.85
Dividend Yield
3.39%
Stryker stock logo

14. Stryker NYSE:SYK

$374.57 +0.65 (+0.17%)
Closing price 03:59 PM Eastern
Extended Trading
$371.00 -3.57 (-0.95%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Recent analyst upgrades have increased price targets significantly, with some analysts setting targets as high as $445.00, indicating strong potential for stock appreciation.
  • The current stock price is around $369.48, which may present a buying opportunity for investors looking to enter at a lower price point before potential gains.
  • Institutional investors and hedge funds own over 77% of Stryker Co.'s stock, suggesting strong confidence in the company's future performance.

Cons of Stryker

  • Insider selling activity has been noted, with significant shares sold by directors, which could indicate a lack of confidence in the stock's short-term performance.
  • Despite positive analyst ratings, the stock has shown volatility, which may pose risks for investors seeking stable returns.
  • With a high percentage of institutional ownership, any significant sell-off by these investors could negatively impact the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$142.97 billion
P/E Ratio
48.27
Consensus Rating
Moderate Buy
Consensus Price Target
$424.56 (+13.3% Upside)
Volume
1.63 million shares
Average Volume
1.35 million shares
Today's Range
$368.54
$376.18
50-Day Range
$336.96
$396.10
52-Week Range
$314.93
$406.19
Dividend Yield
0.92%
Danaher stock logo

15. Danaher NYSE:DHR

$196.90 -2.43 (-1.22%)
Closing price 03:59 PM Eastern
Extended Trading
$197.91 +1.01 (+0.51%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. recently reported strong quarterly earnings, with earnings per share of $1.88, surpassing analyst expectations significantly, indicating robust financial health.
  • The company has a solid revenue stream, generating $5.74 billion in the latest quarter, which exceeded analyst estimates, showcasing its ability to perform well in the market.
  • Danaher Co. has increased its quarterly dividend to $0.32 per share, reflecting a commitment to returning value to shareholders, which can be attractive for income-focused investors.

Cons of Danaher

  • The stock has experienced volatility, with a 52-week high of $281.70 and a low of $171.00, indicating potential risks associated with price fluctuations.
  • Analysts have mixed ratings, with five holding a "hold" rating, suggesting that some investors may be cautious about the stock's future performance.
  • Danaher Co. has a relatively high P/E ratio of 37.47, which may indicate that the stock is overvalued compared to its earnings, posing a risk for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.92 billion
P/E Ratio
37.29
Consensus Rating
Moderate Buy
Consensus Price Target
$264.40 (+34.3% Upside)
Volume
3.69 million shares
Average Volume
3.37 million shares
Today's Range
$196.28
$200.32
50-Day Range
$173.85
$214.76
52-Week Range
$171.00
$281.70
Dividend Yield
0.65%
Sanofi stock logo

16. Sanofi NASDAQ:SNY

$54.10 -0.85 (-1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$53.80 -0.30 (-0.55%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi's stock has shown positive momentum, with the current stock price around $53, indicating a potential for growth.
  • Recent upgrades from analysts, including a "strong-buy" rating from Sanford C. Bernstein, suggest confidence in the company's future performance.
  • Institutional investors have been increasing their stakes in Sanofi, reflecting a strong belief in the company's long-term value.

Cons of Sanofi

  • Despite recent positive ratings, the stock has faced volatility, which can be a concern for risk-averse investors.
  • Sanofi's market performance may be impacted by competitive pressures in the pharmaceutical industry, which could affect its market share.
  • Some analysts have issued hold ratings, indicating uncertainty about the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$136.67 billion
P/E Ratio
21.73
Consensus Rating
Buy
Consensus Price Target
$63.33 (+17.1% Upside)
Volume
1.51 million shares
Average Volume
2.35 million shares
Today's Range
$53.94
$55.13
50-Day Range
$49.66
$59.42
52-Week Range
$45.80
$60.12
Dividend Yield
2.83%
Pfizer stock logo

17. Pfizer NYSE:PFE

$23.91 -0.50 (-2.06%)
Closing price 03:59 PM Eastern
Extended Trading
$24.03 +0.12 (+0.51%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $24.00, which is considered attractive by some analysts, suggesting potential for growth.
  • Pfizer Inc. recently reported earnings per share of $0.92, exceeding analysts' expectations, indicating strong financial performance.
  • The company has a consensus rating of "Moderate Buy" from analysts, reflecting overall positive sentiment towards its future prospects.

Cons of Pfizer

  • Analysts have issued several neutral ratings, indicating a lack of strong bullish sentiment and potential concerns about future growth.
  • The company's dividend payout ratio is currently over 121%, suggesting that it may be paying out more in dividends than it earns, which could be unsustainable.
  • Some analysts have reduced their price targets for Pfizer Inc., indicating a cautious outlook on the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$135.59 billion
P/E Ratio
16.96
Consensus Rating
Moderate Buy
Consensus Price Target
$29.64 (+24.0% Upside)
Volume
46.87 million shares
Average Volume
40.68 million shares
Today's Range
$23.80
$24.33
50-Day Range
$21.57
$26.76
52-Week Range
$20.92
$31.54
Dividend Yield
7.46%
Gilead Sciences stock logo

18. Gilead Sciences NASDAQ:GILD

$103.25 -3.29 (-3.09%)
Closing price 04:00 PM Eastern
Extended Trading
$103.20 -0.05 (-0.04%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The company recently reported earnings per share (EPS) of $1.90, surpassing analyst expectations, which indicates strong financial performance and potential for future growth.
  • Gilead Sciences, Inc. has increased its quarterly dividend to $0.79 per share, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend yield of approximately 2.95%, which can be attractive for income-focused investors.
  • Analysts have set optimistic price targets for Gilead Sciences, Inc., with several firms raising their targets significantly, suggesting a positive outlook for the stock's future performance.

Cons of Gilead Sciences

  • The company's net margin is relatively low at 1.67%, which may raise concerns about profitability and operational efficiency compared to industry peers.
  • Gilead Sciences, Inc. has a very high dividend payout ratio of 854.05%, suggesting that a significant portion of earnings is being paid out as dividends, which could limit reinvestment in growth opportunities.
  • Insider selling has been notable, with the CFO recently selling a substantial number of shares, which could signal a lack of confidence in the company's short-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$128.56 billion
P/E Ratio
279.05
Consensus Rating
Moderate Buy
Consensus Price Target
$110.55 (+7.1% Upside)
Volume
7.27 million shares
Average Volume
7.52 million shares
Today's Range
$103.16
$105.86
50-Day Range
$101.40
$117.41
52-Week Range
$62.07
$119.96
Dividend Yield
3.06%
Vertex Pharmaceuticals stock logo

19. Vertex Pharmaceuticals NASDAQ:VRTX

$498.86 -10.64 (-2.09%)
Closing price 04:00 PM Eastern
Extended Trading
$501.80 +2.94 (+0.59%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is approximately $492, which reflects a strong market position and investor interest.
  • Vertex Pharmaceuticals has a solid market capitalization of $126.45 billion, indicating a robust financial foundation and potential for growth.
  • The company has a low debt-to-equity ratio of 0.01, suggesting financial stability and lower risk associated with debt obligations.

Cons of Vertex Pharmaceuticals

  • The company reported earnings per share of $3.54, missing analysts' expectations, which may raise concerns about its short-term profitability.
  • Vertex Pharmaceuticals has a negative net margin of 4.86%, indicating that the company is currently spending more than it earns, which could affect future growth.
  • The stock has a high price-to-earnings ratio of -223.83, suggesting that the stock may be overvalued relative to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$128.25 billion
P/E Ratio
-226.75
Consensus Rating
Moderate Buy
Consensus Price Target
$514.91 (+3.2% Upside)
Volume
1.45 million shares
Average Volume
1.34 million shares
Today's Range
$498.21
$507.75
50-Day Range
$472.37
$513.76
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Medtronic stock logo

20. Medtronic NYSE:MDT

$83.43 -1.33 (-1.57%)
Closing price 03:59 PM Eastern
Extended Trading
$83.31 -0.12 (-0.15%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc recently reported earnings per share (EPS) of $1.39, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • The company has a solid dividend yield of approximately 3.33%, providing investors with a reliable income stream through dividends.
  • Analysts have a consensus rating of "Hold" with an average price target of around $96.14, suggesting that the stock has room for appreciation based on current market conditions.

Cons of Medtronic

  • The company reported revenue of $8.29 billion, slightly below analyst expectations, which may raise concerns about future growth prospects.
  • Medtronic plc has a high dividend payout ratio of 85.11%, which could limit its ability to reinvest in growth opportunities or weather economic downturns.
  • Recent price target adjustments by analysts, including reductions from some brokerages, may indicate a lack of confidence in the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$107.01 billion
P/E Ratio
25.36
Consensus Rating
Hold
Consensus Price Target
$96.14 (+15.2% Upside)
Volume
6.01 million shares
Average Volume
6.68 million shares
Today's Range
$82.95
$84.48
50-Day Range
$81.64
$94.58
52-Week Range
$75.96
$96.25
Dividend Yield
3.33%
Bristol-Myers Squibb stock logo

21. Bristol-Myers Squibb NYSE:BMY

$49.53 -0.67 (-1.34%)
Closing price 03:59 PM Eastern
Extended Trading
$49.45 -0.08 (-0.16%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

  • The current stock price is around $55, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.
  • The company has received positive ratings from several analysts, with a consensus target price of approximately $57.67, indicating potential upside for investors.

Cons of Bristol-Myers Squibb

  • The payout ratio is currently negative, indicating that the company may not be returning profits to shareholders through dividends, which could be a concern for income-focused investors.
  • Some analysts have downgraded their price targets for Bristol-Myers Squibb, reflecting cautious sentiment about the company's near-term performance.
  • There are ongoing competitive pressures in the pharmaceutical industry, particularly in oncology, which could impact Bristol-Myers Squibb's market position and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$100.79 billion
P/E Ratio
-11.21
Consensus Rating
Hold
Consensus Price Target
$58.00 (+17.1% Upside)
Volume
17.16 million shares
Average Volume
12.97 million shares
Today's Range
$48.69
$50.18
50-Day Range
$47.86
$63.00
52-Week Range
$39.35
$63.33
Dividend Yield
5.12%
Elevance Health stock logo

22. Elevance Health NYSE:ELV

$408.52 -12.06 (-2.87%)
Closing price 03:59 PM Eastern
Extended Trading
$408.69 +0.17 (+0.04%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$92.30 billion
P/E Ratio
15.95
Consensus Rating
Moderate Buy
Consensus Price Target
$510.38 (+24.9% Upside)
Volume
1.32 million shares
Average Volume
1.47 million shares
Today's Range
$408.11
$419.38
50-Day Range
$386.22
$452.70
52-Week Range
$362.21
$567.26
Dividend Yield
1.62%
The Cigna Group stock logo

23. The Cigna Group NYSE:CI

$335.21 -4.83 (-1.42%)
Closing price 03:59 PM Eastern
Extended Trading
$334.92 -0.29 (-0.09%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about The Cigna Group

Pros of The Cigna Group

  • The current stock price is around $335, reflecting a recent increase, which may indicate positive market sentiment and potential for further growth.
  • The Cigna Group has a strong market capitalization of approximately $91 billion, suggesting stability and a solid position in the health services sector.
  • The company recently increased its quarterly dividend to $1.51 per share, representing a yield of about 1.80%, which can provide a steady income stream for investors.

Cons of The Cigna Group

  • The company recently missed earnings expectations, reporting $6.64 per share against a consensus estimate of $7.84, which may raise concerns about its financial performance.
  • Insider selling has been noted, with significant shares sold recently, which could signal a lack of confidence from those closest to the company.
  • The stock has a relatively high price-to-earnings (P/E) ratio of around 27, which may suggest that it is overvalued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$91.74 billion
P/E Ratio
27.39
Consensus Rating
Buy
Consensus Price Target
$373.56 (+11.4% Upside)
Volume
1.99 million shares
Average Volume
1.70 million shares
Today's Range
$334.66
$341.40
50-Day Range
$303.39
$340.21
52-Week Range
$262.03
$370.83
Dividend Yield
1.80%
McKesson stock logo

24. McKesson NYSE:MCK

$706.54 -6.25 (-0.88%)
Closing price 03:59 PM Eastern
Extended Trading
$708.16 +1.62 (+0.23%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $697, reflecting a strong market position and potential for growth.
  • Recent upgrades from major analysts, including a price target increase to $755, indicate positive market sentiment and confidence in the company's future performance.
  • McKesson Co. has a solid dividend yield of 0.41%, providing investors with a steady income stream, which is particularly attractive in uncertain market conditions.

Cons of McKesson

  • Recent insider selling, including significant shares sold by the CEO, may raise concerns about the company's future outlook and management's confidence in its performance.
  • The stock has experienced fluctuations, with a 1-year low of $464.42, indicating potential volatility that could deter risk-averse investors.
  • Despite positive ratings, there are still three analysts who have rated the stock as a hold, suggesting some uncertainty about its short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$88.55 billion
P/E Ratio
32.35
Consensus Rating
Moderate Buy
Consensus Price Target
$681.00 (-3.6% Downside)
Volume
957,600 shares
Average Volume
889,817 shares
Today's Range
$698.74
$714.90
50-Day Range
$621.03
$716.71
52-Week Range
$464.42
$728.32
Dividend Yield
0.41%
CVS Health stock logo

25. CVS Health NYSE:CVS

$69.42 +2.71 (+4.06%)
Closing price 03:59 PM Eastern
Extended Trading
$69.57 +0.16 (+0.22%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. has received multiple upgrades from analysts, indicating strong confidence in its future performance. Recent ratings include an "overweight" from Morgan Stanley and a "strong buy" from Leerink Partners.
  • The stock price is currently around $65.86, which is significantly higher than its one-year low of $43.56, suggesting a positive trend in its market performance.
  • Analysts have set an average price target of approximately $71.83, which indicates potential upside for investors based on current trading levels.

Cons of CVS Health

  • Despite recent upgrades, there are still four analysts who have rated the stock as a hold, indicating some uncertainty about its future performance.
  • The stock has a beta of 0.57, which suggests lower volatility compared to the market, but may also indicate limited growth potential in a bullish market.
  • Insider trading activity shows that a senior vice president sold a significant number of shares recently, which could raise concerns about the company's short-term outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$87.52 billion
P/E Ratio
18.97
Consensus Rating
Moderate Buy
Consensus Price Target
$71.94 (+3.6% Upside)
Volume
20.87 million shares
Average Volume
11.65 million shares
Today's Range
$69.27
$72.51
50-Day Range
$63.54
$70.40
52-Week Range
$43.56
$72.51
Dividend Yield
4.10%
HCA Healthcare stock logo

26. HCA Healthcare NYSE:HCA

$342.93 -2.15 (-0.62%)
Closing price 03:59 PM Eastern
Extended Trading
$343.00 +0.07 (+0.02%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • HCA Healthcare, Inc. recently reported earnings per share (EPS) of $6.22, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • The company has a high return on equity, suggesting effective management and profitability, which can attract investors looking for solid returns.
  • HCA Healthcare, Inc. has increased its quarterly dividend to $0.72 per share, reflecting a commitment to returning value to shareholders and indicating financial stability.

Cons of HCA Healthcare

  • The company has a relatively high debt-to-equity ratio, which may indicate financial risk and could affect its ability to manage debt obligations effectively.
  • HCA Healthcare, Inc. operates in a highly competitive healthcare market, which can impact its market share and profitability.
  • Recent insider selling activity may raise concerns about the confidence of executives in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$84.43 billion
P/E Ratio
15.61
Consensus Rating
Moderate Buy
Consensus Price Target
$381.13 (+11.1% Upside)
Volume
1.15 million shares
Average Volume
1.40 million shares
Today's Range
$340.96
$348.14
50-Day Range
$305.79
$349.03
52-Week Range
$289.98
$417.14
Dividend Yield
0.84%
GSK stock logo

27. GSK NYSE:GSK

$38.74 -1.11 (-2.77%)
Closing price 03:59 PM Eastern
Extended Trading
$38.80 +0.05 (+0.13%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $35.92, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc has recently seen significant institutional interest, with hedge funds and other institutional investors owning approximately 15.74% of the company's stock, indicating confidence in its future performance.
  • Analysts have a consensus rating of "Moderate Buy" for GSK plc, with a price target of around $40.58, suggesting potential upside for investors.

Cons of GSK

  • Federated Hermes Inc. recently reduced its stake in GSK plc by 16.2%, which may signal concerns about the company's short-term performance.
  • Some analysts have downgraded their ratings, with StockNews.com cutting GSK from a "strong-buy" to a "buy," indicating a more cautious outlook.
  • The stock has experienced volatility, with a 1-year low of $31.72, suggesting potential risks for investors regarding price stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$79.94 billion
P/E Ratio
24.37
Consensus Rating
Hold
Consensus Price Target
$40.58 (+4.7% Upside)
Volume
4.45 million shares
Average Volume
4.75 million shares
Today's Range
$38.72
$39.42
50-Day Range
$33.65
$40.41
52-Week Range
$31.72
$45.93
Dividend Yield
4.28%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$155.72 -0.68 (-0.43%)
Closing price 03:59 PM Eastern
Extended Trading
$152.52 -3.20 (-2.06%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $151, reflecting a stable market position and potential for growth.
  • Zoetis Inc. reported a strong earnings per share (EPS) of $1.40, exceeding analysts' expectations, indicating robust financial health.
  • The company has a high net margin, suggesting effective cost management and profitability, which can lead to higher returns for investors.

Cons of Zoetis

  • The stock has experienced fluctuations, with a recent decline of about 1.2%, which may indicate volatility in the market.
  • Despite strong earnings, the price-to-earnings ratio is relatively high, suggesting that the stock may be overvalued compared to its earnings potential.
  • Institutional ownership is high, which can lead to increased volatility if large investors decide to sell their shares.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$69.48 billion
P/E Ratio
28.47
Consensus Rating
Buy
Consensus Price Target
$214.40 (+37.7% Upside)
Volume
1.93 million shares
Average Volume
2.48 million shares
Today's Range
$152.30
$157.42
50-Day Range
$144.09
$171.70
52-Week Range
$139.70
$200.33
Dividend Yield
1.30%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$590.00 -8.76 (-1.46%)
Closing price 04:00 PM Eastern
Extended Trading
$591.50 +1.50 (+0.25%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $587.85, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Regeneron Pharmaceuticals, Inc. reported a strong quarterly earnings performance, with earnings per share (EPS) of $12.07, exceeding analysts' expectations, indicating robust financial health.
  • The company has a high net margin of over 31%, suggesting efficient management and profitability, which can be attractive to investors seeking stable returns.

Cons of Regeneron Pharmaceuticals

  • The stock has experienced a decline from its 52-week high of $1,211.20, which may raise concerns about its current valuation and future performance.
  • Analysts have recently lowered their price targets for the stock, indicating a potential lack of confidence in its short-term growth prospects.
  • The company has a PEG ratio of 2.34, which suggests that the stock may be overvalued relative to its earnings growth rate, a consideration for value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$64.50 billion
P/E Ratio
15.41
Consensus Rating
Moderate Buy
Consensus Price Target
$892.60 (+51.3% Upside)
Volume
1.19 million shares
Average Volume
742,073 shares
Today's Range
$578.50
$593.94
50-Day Range
$546.39
$744.83
52-Week Range
$525.99
$1,211.20
Dividend Yield
0.14%
Cencora stock logo

30. Cencora NYSE:COR

$290.46 -2.21 (-0.76%)
Closing price 03:59 PM Eastern
Extended Trading
$290.50 +0.04 (+0.01%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is approximately $289.33, which reflects a strong market position and investor interest.
  • Recent insider transactions indicate confidence in the company's future, with executives selling shares at high prices, suggesting they believe the stock is valued well.
  • Cencora, Inc. has a solid market presence in sourcing and distributing pharmaceutical products, which is a growing industry with increasing demand.

Cons of Cencora

  • Recent insider sales, while indicating confidence, also represent a decrease in their positions, which could signal potential concerns about future performance.
  • The pharmaceutical distribution industry is highly competitive, and Cencora, Inc. may face challenges from larger players with more resources.
  • Market volatility can impact stock prices significantly, and recent fluctuations may lead to uncertainty for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.32 billion
P/E Ratio
41.32
Consensus Rating
Moderate Buy
Consensus Price Target
$290.00 (-0.2% Downside)
Volume
1.10 million shares
Average Volume
1.52 million shares
Today's Range
$286.76
$292.45
50-Day Range
$244.34
$292.76
52-Week Range
$214.77
$296.65
Dividend Yield
0.76%
Becton, Dickinson and Company stock logo

31. Becton, Dickinson and Company NYSE:BDX

$169.56 -37.53 (-18.12%)
Closing price 03:59 PM Eastern
Extended Trading
$170.30 +0.74 (+0.44%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company has received multiple upgrades from analysts, indicating strong confidence in its future performance. Recent upgrades include a shift from a "hold" to a "buy" rating.
  • Analysts have set an average price target of approximately $275.71, suggesting potential for price appreciation from the current stock price, which is around $261.
  • Becton, Dickinson and Company has a solid reputation in the healthcare sector, developing and manufacturing essential medical supplies and devices, which are in high demand.

Cons of Becton, Dickinson and Company

  • Despite positive ratings, the stock has seen fluctuations, and recent price targets have been adjusted downward, which may indicate potential volatility.
  • Insider selling activity has occurred, with executives selling shares, which could signal a lack of confidence in the stock's short-term performance.
  • The healthcare sector can be highly competitive and subject to regulatory changes, which may impact the company's profitability and growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.69 billion
P/E Ratio
28.17
Consensus Rating
Moderate Buy
Consensus Price Target
$262.50 (+54.8% Upside)
Volume
13.15 million shares
Average Volume
1.78 million shares
Today's Range
$169.52
$188.00
50-Day Range
$169.56
$232.12
52-Week Range
$169.52
$251.99
Dividend Yield
2.02%
Takeda Pharmaceutical stock logo

32. Takeda Pharmaceutical NYSE:TAK

$15.02 -0.27 (-1.73%)
Closing price 03:59 PM Eastern
Extended Trading
$15.12 +0.10 (+0.66%)
As of 06:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $15.00, which is near its 12-month high, indicating strong market performance and potential for further growth.
  • Takeda Pharmaceutical Company Limited recently reported earnings per share of $0.42, surpassing analyst expectations, which reflects strong operational performance and profitability.
  • The company has a solid market capitalization of approximately $47.71 billion, suggesting stability and a significant presence in the pharmaceutical industry.

Cons of Takeda Pharmaceutical

  • The stock has experienced a slight decline of about 0.3% recently, which may indicate short-term volatility and investor uncertainty.
  • With a debt-to-equity ratio of 0.63, the company carries a moderate level of debt, which could pose risks in times of economic downturns or if interest rates rise.
  • Despite recent earnings growth, the company's net margin of 4.53% suggests that profitability may be under pressure, which could affect future earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.81 billion
P/E Ratio
37.56
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
1.67 million shares
Average Volume
1.87 million shares
Today's Range
$15.01
$15.20
50-Day Range
$13.87
$15.33
52-Week Range
$12.58
$15.37
Dividend Yield
3.56%
Alcon stock logo

33. Alcon NYSE:ALC

$96.15 -1.46 (-1.50%)
Closing price 03:59 PM Eastern
Extended Trading
$96.13 -0.02 (-0.02%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.98, reflecting a positive trend in the company's market performance.
  • Alcon Inc. has shown a strong fifty-two week performance, with an increase of approximately 26.72%, indicating robust growth potential.
  • The company maintains a significant institutional ownership percentage of about 72.64%, suggesting confidence from large investors in its future prospects.

Cons of Alcon

  • The company has experienced a month-to-month increase in shares shorted, which could indicate growing bearish sentiment among investors.
  • Days to cover is relatively high at 4.5, suggesting that if many investors decide to sell short, it could take longer to cover those positions, potentially leading to price pressure.
  • Despite recent performance, the overall market conditions can be unpredictable, which may affect Alcon Inc.'s stock price negatively.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.43 billion
P/E Ratio
41.09
Consensus Rating
Moderate Buy
Consensus Price Target
$106.22 (+10.5% Upside)
Volume
766,344 shares
Average Volume
1.05 million shares
Today's Range
$95.70
$97.55
50-Day Range
$82.86
$97.63
52-Week Range
$77.76
$101.10
Dividend Yield
0.28%
Haleon stock logo

34. Haleon NYSE:HLN

$10.30 +0.16 (+1.53%)
Closing price 03:59 PM Eastern
Extended Trading
$10.26 -0.04 (-0.39%)
As of 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $9.53, which reflects a recent increase of 2.8%, indicating positive market sentiment.
  • Haleon plc has announced a dividend of $0.1166, representing a yield of 1.6%, which can provide a steady income stream for investors.
  • The company has shown strong institutional interest, with significant increases in holdings from major investors, suggesting confidence in its future performance.

Cons of Haleon

  • The price-to-earnings ratio of 28.02 may indicate that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • Despite recent revenue growth, the earnings per share (EPS) forecast for the current year is only 0.43, which may not meet investor expectations for growth.
  • The company has a relatively high PEG ratio of 2.82, suggesting that the stock price may not be justified by its earnings growth rate.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.49 billion
P/E Ratio
30.31
Consensus Rating
Hold
Consensus Price Target
$10.95 (+6.3% Upside)
Volume
14.69 million shares
Average Volume
7.52 million shares
Today's Range
$10.29
$10.46
50-Day Range
$9.28
$10.68
52-Week Range
$8.12
$10.80
Dividend Yield
2.28%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$75.31 -0.18 (-0.24%)
Closing price 03:59 PM Eastern
Extended Trading
$74.50 -0.81 (-1.08%)
As of 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $70.71, which may present a buying opportunity for investors looking for growth in the medical technology sector.
  • Edwards Lifesciences Co. reported a strong quarterly earnings result, exceeding analysts' expectations with an earnings per share of $0.59, indicating solid financial performance.
  • Analysts have a generally positive outlook on the stock, with several upgrades and a consensus average target price of approximately $78.55, suggesting potential for price appreciation.

Cons of Edwards Lifesciences

  • Insider selling has been notable, with a total of 71,853 shares sold recently, which may indicate a lack of confidence among executives regarding the company's short-term prospects.
  • Some analysts have downgraded the stock, with a "strong sell" rating from Wolfe Research, suggesting potential concerns about the company's future performance.
  • The stock has experienced fluctuations, with a 52-week high of $95.25 and a low of $58.93, indicating volatility that could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.27 billion
P/E Ratio
10.81
Consensus Rating
Hold
Consensus Price Target
$79.45 (+5.5% Upside)
Volume
3.88 million shares
Average Volume
5.01 million shares
Today's Range
$74.15
$75.82
50-Day Range
$67.04
$76.28
52-Week Range
$58.93
$95.25
Dividend Yield
N/A
argenx stock logo

36. argenx NASDAQ:ARGX

$639.90 -5.24 (-0.81%)
Closing price 04:00 PM Eastern
Extended Trading
$639.28 -0.62 (-0.10%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenx

Pros of argenx

  • The current stock price is around $802, which reflects strong investor interest and confidence in the company's growth potential.
  • argenx SE is actively developing innovative therapies for various autoimmune diseases, with its lead product candidate, efgartigimod, showing promise in treating conditions like myasthenia gravis and immune thrombocytopenia.
  • Institutional investors hold a significant portion of the stock, indicating strong support and confidence from major financial entities, which can be a positive signal for retail investors.

Cons of argenx

  • Despite its promising pipeline, the biotechnology sector is highly volatile, and the success of drug candidates is uncertain, which can lead to significant stock price fluctuations.
  • Recent market trends show that biotechnology stocks can be sensitive to regulatory changes and approval processes, which may impact argenx SE's ability to bring products to market.
  • The company faces competition from other biotechnology firms developing similar therapies, which could affect its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.07 billion
P/E Ratio
-727.16
Consensus Rating
Moderate Buy
Consensus Price Target
$699.28 (+9.3% Upside)
Volume
181,899 shares
Average Volume
308,708 shares
Today's Range
$631.08
$645.60
50-Day Range
$546.22
$645.14
52-Week Range
$352.77
$678.21
Dividend Yield
N/A
IDEXX Laboratories stock logo

37. IDEXX Laboratories NASDAQ:IDXX

$471.38 +38.73 (+8.95%)
Closing price 04:00 PM Eastern
Extended Trading
$471.68 +0.30 (+0.06%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $437, reflecting a strong market presence and potential for growth.
  • Recent analyst upgrades indicate positive sentiment, with several firms raising their price targets, suggesting confidence in the company's future performance.
  • IDEXX Laboratories, Inc. has a diverse product portfolio catering to various markets, including veterinary and water testing, which can help mitigate risks associated with market fluctuations.

Cons of IDEXX Laboratories

  • The stock has experienced volatility, with recent trading down about 0.8%, which may indicate market uncertainty or investor concerns.
  • Analyst ratings are mixed, with some firms downgrading their ratings, suggesting that not all market participants are confident in the company's near-term prospects.
  • The company's price-to-earnings (P/E) ratio is relatively high, which could indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.20 billion
P/E Ratio
44.18
Consensus Rating
Moderate Buy
Consensus Price Target
$523.75 (+11.1% Upside)
Volume
1.40 million shares
Average Volume
639,482 shares
Today's Range
$462.05
$481.93
50-Day Range
$361.04
$471.38
52-Week Range
$356.14
$548.88
Dividend Yield
N/A
Veeva Systems stock logo

38. Veeva Systems NYSE:VEEV

$232.21 -1.48 (-0.63%)
Closing price 03:59 PM Eastern
Extended Trading
$226.57 -5.64 (-2.43%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $226, which is near its fifty-day moving average, indicating potential stability in the short term.
  • Veeva Systems Inc. has a strong market capitalization of approximately $34.14 billion, suggesting a solid position in the market and potential for growth.
  • The company has a price-to-earnings ratio of 51.81, which, while high, reflects investor confidence in its future earnings potential.

Cons of Veeva Systems

  • The price-to-earnings-growth ratio of 1.89 suggests that the stock may be overvalued relative to its growth rate, which could deter value-focused investors.
  • Recent analyst ratings have been mixed, with some firms downgrading their ratings and target prices, indicating uncertainty about future performance.
  • Insider selling has occurred recently, with significant shares sold by executives, which could signal a lack of confidence in the stock's near-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.02 billion
P/E Ratio
57.34
Consensus Rating
Moderate Buy
Consensus Price Target
$254.92 (+9.8% Upside)
Volume
750,262 shares
Average Volume
1.08 million shares
Today's Range
$231.19
$235.00
50-Day Range
$209.34
$247.10
52-Week Range
$170.25
$258.93
Dividend Yield
N/A
ResMed stock logo

39. ResMed NYSE:RMD

$236.29 -0.30 (-0.13%)
Closing price 03:59 PM Eastern
Extended Trading
$236.46 +0.18 (+0.07%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $209, which is significantly lower than its 52-week high of $263.05, potentially offering a buying opportunity for investors looking for value.
  • ResMed Inc. has demonstrated strong financial performance, with a recent earnings per share (EPS) of $2.43, surpassing analyst expectations, indicating robust profitability.
  • The company has a solid market capitalization of approximately $31.27 billion, reflecting its strong position in the medical equipment sector and investor confidence.

Cons of ResMed

  • Despite strong earnings, the stock has a P/E ratio of 25.13, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been notable, with executives selling a total of 49,013 shares recently, which could signal a lack of confidence in the stock's short-term performance.
  • The company has a beta of 0.75, suggesting lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.65 billion
P/E Ratio
27.90
Consensus Rating
Moderate Buy
Consensus Price Target
$258.83 (+9.5% Upside)
Volume
732,155 shares
Average Volume
1.01 million shares
Today's Range
$233.87
$238.81
50-Day Range
$204.54
$237.72
52-Week Range
$179.42
$263.05
Dividend Yield
0.89%
Cardinal Health stock logo

40. Cardinal Health NYSE:CAH

$145.46 +4.17 (+2.95%)
Closing price 03:59 PM Eastern
Extended Trading
$144.86 -0.60 (-0.41%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $137.64, reflecting a strong performance in the market.
  • Recent earnings reports show that Cardinal Health, Inc. exceeded analysts' expectations, reporting earnings per share of $1.93, which is a positive indicator of financial health.
  • Analysts have a consensus rating of "Moderate Buy" for Cardinal Health, Inc., suggesting confidence in the company's future performance.

Cons of Cardinal Health

  • The company has a negative return on equity of 59.57%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Despite recent upgrades, there are still four analysts who have rated the stock as a hold, indicating some uncertainty about its future performance.
  • Cardinal Health, Inc. has a relatively low net margin of 0.59%, suggesting that it may face challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.13 billion
P/E Ratio
27.14
Consensus Rating
Moderate Buy
Consensus Price Target
$142.36 (-2.1% Downside)
Volume
4.03 million shares
Average Volume
2.20 million shares
Today's Range
$136.71
$147.27
50-Day Range
$124.07
$145.46
52-Week Range
$93.17
$147.27
Dividend Yield
1.45%
Alnylam Pharmaceuticals stock logo

41. Alnylam Pharmaceuticals NASDAQ:ALNY

$255.13 -8.11 (-3.08%)
Closing price 04:00 PM Eastern
Extended Trading
$260.00 +4.87 (+1.91%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The current stock price is around $254.85, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • Alnylam Pharmaceuticals, Inc. has a strong pipeline of innovative therapeutics, including ONPATTRO and AMVUTTRA, which are already marketed and address significant medical needs.
  • Recent analyst ratings indicate a consensus of "Moderate Buy" with a price target averaging around $315.58, suggesting potential upside for investors.

Cons of Alnylam Pharmaceuticals

  • The stock has a high price-to-earnings ratio, indicating that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Insider sales have occurred recently, with executives selling shares, which might raise concerns about their confidence in the company's future performance.
  • Market volatility in the biopharmaceutical sector can lead to unpredictable stock performance, which may pose risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.19 billion
P/E Ratio
-117.57
Consensus Rating
Moderate Buy
Consensus Price Target
$315.58 (+23.7% Upside)
Volume
1.52 million shares
Average Volume
884,831 shares
Today's Range
$247.71
$265.91
50-Day Range
$224.32
$290.70
52-Week Range
$144.73
$304.39
Dividend Yield
N/A
GE HealthCare Technologies stock logo

42. GE HealthCare Technologies NASDAQ:GEHC

$67.67 -2.66 (-3.78%)
Closing price 04:00 PM Eastern
Extended Trading
$68.13 +0.46 (+0.68%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • Recent upgrades from multiple financial institutions, including a boost in price targets, indicate strong confidence in the company's future performance.
  • The current stock price is around $68, which may present a buying opportunity given the analysts' average target price of $96.50.
  • GE HealthCare Technologies Inc. reported earnings per share of $1.45, surpassing analysts' expectations, showcasing its strong financial performance.

Cons of GE HealthCare Technologies

  • Despite recent upgrades, the stock has experienced volatility, with a 52-week high of $94.80 and a low of $57.65, indicating potential risks in price stability.
  • The company’s revenue for the last quarter was slightly below analyst estimates, which may raise concerns about future growth prospects.
  • Analysts have mixed ratings, with one sell rating and two hold ratings, suggesting some uncertainty in the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.98 billion
P/E Ratio
15.63
Consensus Rating
Moderate Buy
Consensus Price Target
$89.40 (+32.1% Upside)
Volume
8.11 million shares
Average Volume
3.28 million shares
Today's Range
$67.63
$70.92
50-Day Range
$58.75
$90.81
52-Week Range
$57.65
$94.80
Dividend Yield
0.21%
Humana stock logo

43. Humana NYSE:HUM

$256.11 -6.13 (-2.34%)
Closing price 03:59 PM Eastern
Extended Trading
$254.98 -1.14 (-0.44%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $246, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Humana Inc. has recently received positive ratings from several analysts, with Barclays raising their price target significantly, indicating confidence in the company's future performance.
  • The company reported earnings that exceeded analysts' expectations, showcasing its ability to perform well even in challenging market conditions.

Cons of Humana

  • The stock has experienced a decline of about 7% recently, which may raise concerns about its short-term performance and market sentiment.
  • Analysts have issued mixed ratings, with a significant number maintaining a "hold" rating, suggesting uncertainty about the stock's potential for growth.
  • Humana Inc. has a relatively high P/E ratio, which could indicate that the stock is overvalued compared to its earnings, making it a riskier investment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.91 billion
P/E Ratio
25.74
Consensus Rating
Hold
Consensus Price Target
$287.76 (+12.4% Upside)
Volume
1.75 million shares
Average Volume
1.75 million shares
Today's Range
$255.60
$267.01
50-Day Range
$246.07
$294.97
52-Week Range
$213.31
$406.46
Dividend Yield
1.34%
Agilent Technologies stock logo

44. Agilent Technologies NYSE:A

$106.46 -1.14 (-1.06%)
Closing price 03:59 PM Eastern
Extended Trading
$107.41 +0.95 (+0.89%)
As of 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $100.29, which may present a buying opportunity for investors looking for value in the market.
  • Agilent Technologies, Inc. has received multiple upgrades from analysts, with a consensus rating of "Moderate Buy" and a target price of approximately $144.58, indicating potential for price appreciation.
  • The company has a strong market capitalization of about $28.59 billion, suggesting stability and the ability to invest in growth opportunities.

Cons of Agilent Technologies

  • The stock has experienced a decline of about 2.1% recently, which may indicate short-term volatility and uncertainty in the market.
  • Some analysts have lowered their price targets, with Wells Fargo reducing their target from $155.00 to $135.00, which could reflect concerns about the company's near-term performance.
  • Insider sales have totaled over 5,600 shares in the last ninety days, which might raise questions about the executives' confidence in the company's future prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.35 billion
P/E Ratio
24.47
Consensus Rating
Hold
Consensus Price Target
$143.00 (+34.3% Upside)
Volume
1.52 million shares
Average Volume
1.88 million shares
Today's Range
$104.10
$108.23
50-Day Range
$98.97
$134.51
52-Week Range
$96.43
$155.35
Dividend Yield
0.92%
Centene stock logo

45. Centene NYSE:CNC

$59.39 -0.46 (-0.76%)
Closing price 03:59 PM Eastern
Extended Trading
$59.74 +0.35 (+0.59%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • The current stock price is around $58, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Centene Co. reported strong quarterly earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 3.4%, suggesting growth potential and resilience in its business model.

Cons of Centene

  • Despite recent earnings growth, the company's net margin is relatively low, which may indicate challenges in maintaining profitability.
  • Centene Co. has received mixed ratings from analysts, with some downgrading their price targets, reflecting uncertainty about future performance.
  • The stock has a beta of 0.53, suggesting lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.55 billion
P/E Ratio
9.52
Consensus Rating
Moderate Buy
Consensus Price Target
$79.77 (+34.3% Upside)
Volume
6.05 million shares
Average Volume
4.77 million shares
Today's Range
$58.49
$60.14
50-Day Range
$56.83
$64.37
52-Week Range
$55.03
$80.59
Dividend Yield
N/A
DexCom stock logo

46. DexCom NASDAQ:DXCM

$70.26 -1.12 (-1.57%)
Closing price 04:00 PM Eastern
Extended Trading
$73.04 +2.77 (+3.95%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $68.85, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 52-week high of $139.24.
  • DexCom, Inc. has shown strong institutional support, with 97.75% of its stock owned by institutional investors and hedge funds, indicating confidence in the company's future performance.
  • The company reported a return on equity of 30.14%, suggesting efficient management and profitability, which can be attractive to investors seeking growth.

Cons of DexCom

  • The company recently missed earnings expectations, reporting $0.45 EPS compared to the consensus estimate of $0.50, which may raise concerns about its short-term financial performance.
  • Insider selling has occurred, with corporate insiders selling a total of 105,009 shares worth over $8 million in the last three months, which could signal a lack of confidence in the stock's near-term prospects.
  • The stock has experienced significant volatility, with a beta of 1.50, indicating that it may be more volatile than the overall market, which could be a risk for conservative investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.55 billion
P/E Ratio
49.13
Consensus Rating
Moderate Buy
Consensus Price Target
$99.00 (+40.9% Upside)
Volume
6.87 million shares
Average Volume
4.22 million shares
Today's Range
$69.70
$71.71
50-Day Range
$59.83
$89.91
52-Week Range
$57.52
$132.26
Dividend Yield
N/A
IQVIA stock logo

47. IQVIA NYSE:IQV

$151.02 -4.05 (-2.61%)
Closing price 03:59 PM Eastern
Extended Trading
$150.94 -0.07 (-0.05%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $138.54, which may present a buying opportunity for investors looking for value in the medical research sector.
  • IQVIA Holdings Inc. has a strong return on equity of 28.81%, indicating effective management and profitability, which can attract investors seeking solid financial performance.
  • Analysts have a consensus rating of "Moderate Buy" for IQVIA, with many firms recently issuing buy ratings and price targets that suggest potential for growth.

Cons of IQVIA

  • The company recently reported earnings per share of $2.90, which missed the consensus estimate of $3.11, indicating potential challenges in meeting market expectations.
  • Recent price target reductions by several brokerages, including a drop from $260.00 to $255.00 by UBS Group, may signal concerns about the company's growth trajectory.
  • IQVIA's stock has experienced volatility, with a twelve-month high of $252.88 and a low of $135.97, which could deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.63 billion
P/E Ratio
20.14
Consensus Rating
Moderate Buy
Consensus Price Target
$237.62 (+57.3% Upside)
Volume
1.84 million shares
Average Volume
1.44 million shares
Today's Range
$148.05
$155.00
50-Day Range
$141.38
$191.69
52-Week Range
$135.97
$252.88
Dividend Yield
N/A
Beigene stock logo

48. Beigene NASDAQ:ONC

$255.64 -4.17 (-1.61%)
As of 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Market Capitalization
$25.29 billion
P/E Ratio
-31.02
Consensus Rating
Buy
Consensus Price Target
$318.88 (+24.7% Upside)
Volume
330,862 shares
Average Volume
482,492 shares
Today's Range
$255.59
$261.99
50-Day Range
$206.32
$278.38
52-Week Range
$141.31
$287.88
Dividend Yield
N/A
BioNTech stock logo

49. BioNTech NASDAQ:BNTX

$102.43 -1.72 (-1.65%)
Closing price 04:00 PM Eastern
Extended Trading
$102.91 +0.48 (+0.47%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • BioNTech SE has received multiple "buy" ratings from analysts, indicating strong confidence in its future performance and potential for stock price appreciation.
  • The current stock price is around $104, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 12-month high of approximately $131.
  • Recent earnings reports showed that BioNTech SE exceeded earnings expectations, reporting $1.08 earnings per share, which is significantly higher than the consensus estimate, suggesting strong operational performance.

Cons of BioNTech

  • The company reported a decline in revenue of approximately 19.5% year-over-year, which may raise concerns about its ability to maintain growth in a competitive market.
  • BioNTech SE has a negative return on equity, indicating that the company is not currently generating profit relative to shareholder equity, which could deter potential investors.
  • Analysts project that BioNTech SE will post negative earnings per share for the current fiscal year, suggesting ongoing financial challenges that could impact stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.58 billion
P/E Ratio
-48.78
Consensus Rating
Moderate Buy
Consensus Price Target
$143.44 (+40.0% Upside)
Volume
984,983 shares
Average Volume
912,192 shares
Today's Range
$99.85
$103.71
50-Day Range
$86.65
$120.54
52-Week Range
$76.53
$131.49
Dividend Yield
N/A
Koninklijke Philips stock logo

50. Koninklijke Philips NYSE:PHG

$25.00 -0.35 (-1.38%)
Closing price 03:59 PM Eastern
Extended Trading
$24.98 -0.02 (-0.10%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • Recent upgrades from multiple analysts, including a shift to a "strong-buy" rating, indicate growing confidence in Koninklijke Philips' future performance.
  • The current stock price is around $25.65, which may present a buying opportunity for investors looking for value in the health technology sector.
  • Strong revenue performance, with recent quarterly earnings showing revenue of $5.38 billion, surpassing analyst expectations, suggests robust business operations.

Cons of Koninklijke Philips

  • The company reported a negative net margin of 3.88%, indicating that it is currently spending more than it earns, which could be a concern for profitability.
  • Recent earnings per share (EPS) of $0.54 fell short of analysts' expectations, which may raise doubts about the company's ability to meet future financial targets.
  • Despite a strong revenue figure, the company has a price-to-earnings ratio of -30.53, suggesting that it may not be generating profits relative to its stock price, which can deter potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$23.50 billion
P/E Ratio
-29.76
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
701,922 shares
Average Volume
821,779 shares
Today's Range
$24.79
$25.33
50-Day Range
$21.68
$27.58
52-Week Range
$21.48
$32.91
Dividend Yield
3.62%